Predict risk of dose-related toxicity and responsiveness to 5-FU therapy.

Do not use to screen for celiac disease.  May be used to estimate severity of intestinal villous atrophy in confirmed celiac disease.

May be helpful in evaluating for autoimmune liver disease. For a more comprehensive reflex panel, refer to Autoimmune Liver Disease Evaluation with Reflex to Smooth Muscle Antibody (SMA), IgG by IFA (2007210).

Aid in evaluation of autoimmune liver disease. For a more comprehensive reflex panel, refer to Autoimmune Liver Disease Evaluation with Reflex to Smooth Muscle Antibody (SMA), IgG by IFA (2007210).

Evaluate for possible factor II deficiency. For prothrombin variant testing (inherited thrombotic risk factor), order Prothrombin (F2) c.*97G>A (G20210A) Pathogenic Variant (0056060).

Order to diagnose factor IX deficiency, detect factor IX inhibitors, and monitor factor IX replacement therapy.

Order to diagnose factor IX deficiency (hemophilia B) and monitor factor IX replacement therapy.

Order to detect factor V Leiden variant.

Evaluate for possible factor V deficiency. For factor V Leiden testing, order APC Resistance Profile with Reflex to Factor V Leiden (0030192) or Factor V Leiden (F5) R506Q Mutation (0097720).

Determine thrombotic risk in individuals known to be factor V Leiden heterozygotes.

Evaluate possible factor VII deficiency.

Order to diagnose factor VIII deficiency, detect factor VIII inhibitors, and monitor factor VIII replacement therapy.

Order to diagnose hemophilia A, acquired factor VIII deficiency, or as part of a diagnostic workup for von Willebrand disease. Not recommended when screening for thrombophilia.

Evaluate possible factor X deficiency.

Order to diagnose factor XI deficiency (hemophilia C).

Evaluate the cause of an isolated prolonged PTT in a patient who is not currently bleeding.

Assess genetic risk for thrombosis.

First-line test to diagnose FXIII deficiency. Appropriate for evaluation of patients with a bleeding disorder presenting with normal PT, aPTT, and platelet count test results. Monitor FXIII therapy and confirm abnormalities detected on FXIII qualitative assay.

Most useful for acquired or severe FXIII deficiency testing. Abnormal results should be confirmed with quantitative testing. Refer to Factor XIII Activity (2006182).

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

Acceptable diagnostic or predictive test for familial adenomatous polyposis. For classic FAP, consider Familial Adenomatous Polyposis Panel: (APC) Sequencing and Deletion/Duplication, (MUTYH) 2 Mutations (2004915).

Preferred diagnostic or predictive test for familial adenomatous polyposis and MUTYH-associated polyposis.

Preferred test for suspected familial Mediterranean fever.

Consultation with a genetic counselor is advised. Useful when a pathogenic familial variant identifiable by sequencing is known.

Consultation with a genetic counselor is advised. Order for fetal testing to detect a previously characterized variant in a family member.

Confirm a clinical diagnosis of familial transthyretin (TTR) amyloidosis, familial euthyroid hyperthyroxinemia, or senile systemic amyloidosis.

Carrier screening or diagnostic testing for Fanconi anemia group C for individuals of Ashkenazi Jewish descent.

Measurement of fecal fats can be useful in establishing a diagnosis of pancreatic disease. Testing requires the submission of an entire 24-hour stool collection.
For random stool collections, order Fat, Fecal Qualitative (0020385).
For testing of an aliquot from a 24-, 48-, or 72-hour stool collection, order Fat, Fecal Quantitative, Homogenized Aliquot (2002350).
For complete 48-hour stool collections, order Fat, Fecal Quantitative, 48-Hour Collection (Includes Homogenization) (2002355).
For complete 72-hour stool collections, order Fat, Fecal Quantitative, 72-Hour Collection (Includes Homogenization) (2002356).

Measurement of fecal fats can be useful in establishing a diagnosis of pancreatic disease. Testing requires the submission of an entire 48-hour stool collection.
For random stool collections, order Fat, Fecal Qualitative (0020385)
For testing of an aliquot from a 24-, 48-, or 72-hour stool collection, order Fat, Fecal Quantitative, Homogenized Aliquot (2002350)
For complete 24-hour stool collections, order Fat, Fecal Quantitative, 24-Hour Collection (Includes Homogenization) (2002354)
For complete 72-hour stool collections, order Fat, Fecal Quantitative, 72-Hour Collection (Includes Homogenization) (2002356)

Measurement of fecal fats can be useful in establishing a diagnosis of pancreatic disease. Testing requires the submission of an entire 72-hour stool collection.
For random stool collections, order Fat, Fecal Qualitative (0020385)
For testing of an aliquot from a 24-, 48-, or 72-hour stool collection, order Fat, Fecal Quantitative, Homogenized Aliquot (2002350)
For complete 24-hour stool collections, order Fat, Fecal Quantitative, 24-Hour Collection (Includes Homogenization) (2002354)
For complete 48-hour stool collections, order Fat, Fecal Quantitative, 48-Hour Collection (Includes Homogenization) (2002355)

Measurement of fecal fats can be useful in establishing a diagnosis of pancreatic disease. Testing requires the submission of an aliquot from a 24-, 48-, or 72-hour stool collection.
For random stool collections, order Fat, Fecal Qualitative (0020385).
For complete 24-hour stool collections, order Fat, Fecal Quantitative, 24-Hour Collection (Includes Homogenization) (2002354).
For complete 48-hour stool collections, order Fat, Fecal Quantitative, 48-Hour Collection (Includes Homogenization) (2002355).
For complete 72-hour stool collections, order Fat, Fecal Quantitative, 72-Hour Collection (Includes Homogenization) (2002356).

Identification of patients with essential fatty acid deficiency, evaluation of nutritional status, and diet monitoring.

Confirm presence of disease; not recommended for initial testing.

Optimize drug therapy and monitor patient adherence.

Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out amphetamine exposure. For follow-up testing of a presumptive result, Fentanyl and Metabolite, Urine Quantitative (0092570) is preferred.

Monitor patient adherence.

Preferred test to follow-up presumptive results. For general screening, Fentanyl, Urine Screen with Reflex to Quantitation (2012284) is preferred.

Aid in the diagnosis of iron deficiency anemia and iron overload. Monitor treatment of hemochromatosis.

Assess risk of preterm delivery in less than or equal to 7-14 days from time of sample collection at 24 weeks 0 days to 34 weeks 6 days gestation when there are signs and symptoms of early preterm labor.

Detect and quantify the extent of fetomaternal hemorrhage in pregnant or postpartum women. Assess the need for Rh immunoglobulin (eg, RhoGAM) for fetomaternal hemorrhage.

Recommended for the diagnosis of systemic sclerosis in patients negative for centromere, Scl-70, or RNA polymerase III antibodies. May predict skeletal muscle involvement and pulmonary arterial hypertension.

May be useful for the evaluation of rare disorders such as primary fibrinolysis. For evaluating coagulopathies (eg, disseminated intravascular coagulation), D-Dimer (0030057) is the preferred test.

Determine if fibrinogen deficiency is a potential cause of bleeding.

A follow-up test for decreased fibrinogen activity to determine if the decrease is due to insufficient fibrinogen or dysfunctional fibrinogen.

Assist in diagnosing dysfibrinogenemia.

Confirm diagnosis of ichthyosis vulgaris and differentiate vulgaris from other forms of ichthyosis.

Aid in the detection of antibodies to filaria. Consider Parasites Smear (Giemsa Stain), Blood (0049025).

Optimize drug therapy and monitor patient adherence.

Aid in the diagnosis and management of acute myeloid leukemia.

Optimize drug therapy and monitor patient adherence.

Detect exposure.

Detect exposure.

Screening culture for fluoroquinolone-resistant organisms. Consider prior to trans-rectal prostate biopsy.

Optimize drug therapy and monitor patient adherence.

Optimize drug therapy and monitor patient adherence.

Aids in detection of folate deficiency.

Aids in detection of folate deficiency.

Use in conjunction with histologic and clinical information for the diagnosis of alveolar rhabdomyosarcoma.

Preferred test to diagnose fragile X syndrome and carrier screening in individuals with a positive family history.

Prenatal test for fetuses of mothers with fragile X premutations or full mutations.

Preferred test for detecting antibodies during acute or convalescent phase. Convalescent sera may be required for diagnosis.

Detects antibodies during convalescent phase. Convalescent sera may be required for diagnosis.

Detects antibodies during acute phase; paired concurrent specimen with IgG reduces false positive rate. Convalescent sera may be required for diagnosis.

Direct measure of free estradiol in serum. Most accurate measure of bioactive estradiol.

Diagnostic testing for Freeman-Sheldon syndrome.

May aid in monitoring glucose control for diabetes in specific disorders. Not recommended as a substitute for hemoglobin A1c except in specific populations.

Useful when screening for obstruction or absence of the seminal vesicles in males with azoospermia.

Identify fungi from culture.

Not recommended. Refer to individual fungus-related tests appropriate to patient exposure.

Not recommended. Refer to individual fungal antibody tests, as relevant to patient exposure(s).

Not recommended for the diagnosis of fungal infection of the central nervous system. Refer to individual fungal antibody tests, as relevant to patient exposure(s).

Gold standard test to diagnose fungi as agent of infection.

Identify fungi from culture.

Identify fungus using fungal smear (eg, yeast, aseptate hyphae, septate hyphae).

Use in conjunction with histologic evaluation. Positive FUS rearrangement may support the diagnosis of low-grade fibromyxoid sarcoma (LGFMS).

Determine if  the Fy(a) (FY1) antigen is expressed on the patient's red blood cells. To determine if the patient is heterozygous or homozygous for the Fy(a) antigen, FYB Antigen Typing - Patient (2007725) should also be ordered.

Determine if the Fy(b) (FY2) antigen is expressed on the patient's red blood cells. To determine if the patient is heterozygous or homozygous for the Fy(b) antigen, FYA Antigen Typing - Patient (2007717) should also be ordered.